The goal of the proposed work is to develop a novel antithrombotic drug that is safer and more effective than current therapies. Phase I funding for this project supported the successful development of a novel expression system to facilitate efficient production and purification of an optimized human apyrase as antithrombotic agent. Under Phase II support, we will extend the feasibility studies of Phase I to the development of a commercial Chinese hamster ovary cell line for high yield production. We will then utilize the recombinant protein to determine whether inhibition of platelet activation with the optimized apyrase in vivo attenuates thrombosis after arterial injury in rabbits and pigs. The ultimate goal of this research will be to develop APT102 as a frontline therapy for patients undergoing percutaneous coronary intervention as well as other patients with vascular disorders induced by excessive platelet activation. ? ?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44HL076053-03
Application #
7174862
Study Section
Special Emphasis Panel (ZRG1-HEME-D (10))
Program Officer
Sarkar, Rita
Project Start
2004-01-16
Project End
2009-10-31
Budget Start
2006-11-01
Budget End
2009-10-31
Support Year
3
Fiscal Year
2007
Total Cost
$453,690
Indirect Cost
Name
Apt Therapeutics, Inc.
Department
Type
DUNS #
192266141
City
Saint Louis
State
MO
Country
United States
Zip Code
63108